Gene Editing CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

Gene Editing manufacturers on CDMO Signal: 10 listed, 10 with a Signal Score. Together they have 12 FDA inspections on file (including 7 NAI, 5 VAI and 0 OAI) and 13 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure which steps are done in-house (guide RNA, nuclease, delivery, or edited cells). Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-10-13. Methodology.

Gene Editing CDMOs with the most regulatory evidence on file

Charles River Laboratories
86.3
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
9 FDA inspections · 11 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-01 · NAI
See the evidence →
RoslinCT
79.3
Edinburgh, UK · Hopkinton, MA
1 FDA inspection · 1 EMA/MHRA GMP cert
Last FDA inspection: 2025-01-21 · VAI
See the evidence →
Cedars-Sinai Biomanufacturing
77.3
Los Angeles, CA
2 FDA inspections · 0 EMA/MHRA GMP certs
Last FDA inspection: 2025-03-14 · NAI
See the evidence →
Green Phoenix Labs
78.1
San Diego, CA
0 FDA inspections · 1 EMA/MHRA GMP cert
Last FDA inspection: None on file
See the evidence →
10
CDMOs tracked
10
Fully scored
3
With FDA records
12
FDA inspections
13
EMA/MHRA GMP certs

Gene editing CDMOs support CRISPR, base, and prime editing programs — spanning guide RNA and nuclease (mRNA or protein) supply, delivery (LNP, AAV, or electroporation), and, for ex vivo programs, edited-cell manufacturing.

Because a gene-editing program touches several modalities at once, CDMO selection often hinges on which steps a partner covers in-house versus coordinates. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 7 NAI (no action), 5 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (10), France (4), Germany (3), Ireland (3), UNITED KINGDOM (3).

Last updated 2026-10-13. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
2
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
3
GP
San Diego, CA
78.1 100.0 0 insp · 1 GMP None on file — —
4
AP
Milpitas, CA
59.0 — — None on file — —
5
PO
San Diego, CA
Hiring · 3 open roles
Also makes its own products
58.7 — — None on file — 6 programs
How we score CDMOs →

What to evaluate in a Gene Editing CDMO

Editing components
Confirm supply of guide RNA and nuclease (Cas mRNA or protein) — in-house or sourced — and the quality controls on each.
Delivery modality
In vivo editing needs LNP or AAV delivery; ex vivo needs electroporation and cell handling. Match the CDMO's delivery experience to your approach.
Ex vivo cell manufacturing
For edited cell therapies, evaluate closed-system cell processing and chain-of-identity, as with other cell therapies.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Gene Editing CDMOs — Frequently Asked Questions

How many Gene Editing CDMOs have FDA inspection records?
CDMO Signal tracks 3 Gene Editing CDMOs with FDA inspection records and 13 EMA/MHRA GMP certificates across the group.
What should I look for in a gene editing CDMO?
Map the steps you need — guide RNA and nuclease supply, delivery (LNP/AAV/electroporation), and edited-cell manufacturing — and confirm which the CDMO covers in-house versus coordinates, plus a clean FDA and EMA/MHRA record.
Why do gene editing programs use multiple CDMOs?
A single program may need guide RNA, a nuclease, a delivery vehicle, and cell manufacturing — distinct capabilities. Some CDMOs cover several in-house; many programs combine specialists.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Gene Editing shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Cell Therapy CDMOs AAV / Gene Therapy CDMOs mRNA / LNP CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector